- Around 30,000 new cases of sarcomas are diagnosed every year in the US and EU
- Sarcomas are rare cancers for which treatments and prognoses can vary widely
- The classification and prediction of the metastasis risk is particularly difficult and currently the analysis is based on a histological grade.
- Such analysis is not very accurate and can often leads to sub-optimal patient management
- A molecular signature (67 genes) was identified by a multidisciplinary team of researchers in Bordeaux and published in Nature Medicine in 2010.
- This signature, called CINSARC (Complexity INdex in SARComas), allows the classification of patients into 2 subgroups of good or poor prognosis depending on the metastasis risk.
- Applicable for NGS and CGH-array analysis of frozen and FFPE tumor material
- Efficacy retrospectively validated in the majority of sarcomas through tumor samples
- CINSARC is more predictive than the histological grading
- CINSARC is the future gold standard in sarcoma medical practice
The maturation with Aquitaine Science Transfert led to the validation of the CINSARC signature predictive value
Actions for onCogenesis understanding and Target Identification in ONcology
(ACTION, U 1218)
Patent application: WO 2010/122243 A1